The New York Giants are valued at $10.1B, up 48.5% from the prior recorded valuation. That climb places them in the upper-middle tier of NFL franchises—behind Dallas ($13B) and New England ($6.23B adjusted for recent data), but ahead of most of the league. The jump signals that stadium economics and New York market gravity are finally pricing in at scale. Metlife Stadium generates roughly $550M in annual revenue across events, naming rights, and shared operations. For a market with 20M people and deep-pocketed corporate tenants, that's the foundation. The valuation surge reflects two specific drivers: first, the NFL's media rights explosion—the new 11-year, $76B media deal adds $1.5B+ annually to league coffers, flowing directly to franchise value floors. Second, Metlife's expansion and modernization roadmap has credibly demonstrated that even a shared facility can compete with new single-tenant stadiums on revenue per event. The Giants' stadium economics compound: their MetLife lease runs through 2026, opening negotiation optionality for a premium renewal or new facility agreement. Owner John Mara's patient capital approach—minimal leverage, long-term positioning—has made the franchise an institutional-grade holding. Forward catalysts are clear: a new Metlife deal could push valuation to $11B+, narrowing the gap with Dallas. A successful stadium replacement in New Jersey or New York—conceptually discussed but not funded—would reset the revenue baseline entirely. The risk is simple: franchise performance and postseason revenue remain volatile. But the underlying New York asset, backed by 20M people and corporate seat demand, has proven recession-resistant across two cycles. The Giants now trade at the intersection of market scarcity and stadium modernization—the exact spot institutional capital targets.